Event-Driven Stocks

Keenova Therapeutics plc

Healthcare · Pharmaceutical Preparations · L2 · SEC filings ↗ · Compare ⊕

Signs● 3 good● 3 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$1.43B$1.08B$949.2M$874.6M$2.21B$2.21B
Operating income−$348.2M−$65.9M−$542.0M−$57.8M−$202.9M−$651.6M
Net income−$489.5M$477.9M−$1.63B−$313.1M−$717.4M−$944.6M
Total assets$5.63B$3.30B$3.73B$6.01B$8.92B$9.72B
Total liabilities$3.56B$1.66B$2.57B$4.40B$8.60B$8.70B
Equity$2.07B$1.65B$1.19B$1.61B$313.4M$1.02B
EPS (diluted)$-17.50$24.17$-122.75$-3.69$-8.47$-11.18
Shares out.19.8M19.7M13.2M84.7M84.5M84.2M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−24.3%
Net margin
−34.2%
Return on equity
−23.7%
Return on assets
−8.7%
Return on capital (ROCE)
−7.0%
Liabilities / assets
63.3%
Debt / equity
1.73×
Book value / share
$104.50
Revenue growth (YoY)
32.0%
Net income growth (YoY)
−202.4%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
1.62grey zone
Accruals / assets
−10.9%clean
Beneish M-Score
-1.89normal
Piotroski F-Score
2/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
53
/ 100
Profitability 0Growth 50Catalyst 67Earnings quality 100Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 3 warning● 3 good
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Altman Z″ in the grey zone
  • Revenue is growing year-over-year
  • Positive operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Corporate family

Spun off from Covidien · Jun 28, 2013

From the spin-off filings we track. Follow a company to walk its own history.

Event-driven situations (6)